Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group., G F. Gjerset, M C. Pike, J W. Mosley, J Hassett, Mary A. Fletcher, E Donegan, J W. Parker, R B. Counts, Y Zhou, C K. Kasper
Faculty Articles

Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group., J Hassett, G F. Gjerset, J W. Mosley, Mary A. Fletcher, E Donegan, J W. Parker, R B. Counts, L M. Aledort, H Lee, M C. Pike
Faculty Articles

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group., Mary A. Fletcher, J W. Mosley, J Hassett, G F. Gjerset, J Kaplan, J W. Parker, E Donegan, J M. Lusher, H Lee
Faculty Articles

Lymphocyte immunophenotypes among anti-HTLV-I/II-positive blood donors and recipients. The Transfusion Safety Study Group., Mary A. Fletcher, G F. Gjerset, J Hassett, E Donegan, J W. Parker, J W. Mosley
Faculty Articles

Leukocyte immunophenotyping by flow cytometry in a multisite study: standardization, quality control, and normal values in the Transfusion Safety Study. The Transfusion Safety Study Group., J W. Parker, B Adelsberg, S P. Azen, D Boone, Mary A. Fletcher, G F. Gjerset, J Hassett, J Kaplan, J C. Niland, T Odom-Maryon
Faculty Articles